A Simple, Cost-Effective Microfluidic Device Using a 3D Cross-Flow T-Junction for Producing Decellularized Extracellular Matrix-Derived Microcarriers

IF 3.9 3区 医学 Q2 ENGINEERING, BIOMEDICAL
Farah Kamar, Connor J. Gillis, Grace Bischof, Anorin Ali, John R. de Bruyn, Lauren E. Flynn, Tamie L. Poepping
{"title":"A Simple, Cost-Effective Microfluidic Device Using a 3D Cross-Flow T-Junction for Producing Decellularized Extracellular Matrix-Derived Microcarriers","authors":"Farah Kamar,&nbsp;Connor J. Gillis,&nbsp;Grace Bischof,&nbsp;Anorin Ali,&nbsp;John R. de Bruyn,&nbsp;Lauren E. Flynn,&nbsp;Tamie L. Poepping","doi":"10.1002/jbm.a.37873","DOIUrl":null,"url":null,"abstract":"<p>Cell therapies using human mesenchymal stromal cells (MSCs) are promising for a wide variety of clinical applications. However, broad-scale clinical translation is limited by conventional culture methods for MSC expansion within 2D tissue-culture flasks. MSC expansion on ECM-derived microcarriers within stirred bioreactor systems offers a promising approach to support MSC growth. Previously, our team established methods for fabricating ECM-derived microcarriers from a variety of decellularized tissue sources using electrospraying techniques. However, these microcarriers are relatively large and have a broad size distribution, which may limit their utility. Smaller and more uniform microcarriers may be favorable for MSC growth within bioreactors and have greater potential to serve as a minimally invasive injectable cell delivery platform. To address these limitations, the current project focused on the development of a new microfluidic-based approach enabling both uniform and small microcarrier production. Using a novel, modified 3D T-junction design, we successfully generated microcarriers using human decellularized adipose tissue (DAT) as the ECM source. Our new cost-effective device produced microbeads that were small and monodisperse, at a range of flow rate combinations and with high production rates. Photo-crosslinking using rose bengal allowed for the generation of microcarriers that retained their shape and could withstand rehydration, with a mean diameter of 196 ± 47 μm. Following methods optimization and microcarrier characterization, in vitro studies confirmed that the new microcarriers supported human adipose-derived stromal cell (hASC) attachment and growth, as well as ECM production, across 14 days within spinner flask bioreactors. Overall, this study demonstrates the feasibility of using our novel, cost-effective, and reusable microfluidics device to generate cell-supportive microcarriers comprised exclusively of ECM that show promise as an MSC expansion platform.</p>","PeriodicalId":15142,"journal":{"name":"Journal of biomedical materials research. Part A","volume":"113 2","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jbm.a.37873","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biomedical materials research. Part A","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jbm.a.37873","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Cell therapies using human mesenchymal stromal cells (MSCs) are promising for a wide variety of clinical applications. However, broad-scale clinical translation is limited by conventional culture methods for MSC expansion within 2D tissue-culture flasks. MSC expansion on ECM-derived microcarriers within stirred bioreactor systems offers a promising approach to support MSC growth. Previously, our team established methods for fabricating ECM-derived microcarriers from a variety of decellularized tissue sources using electrospraying techniques. However, these microcarriers are relatively large and have a broad size distribution, which may limit their utility. Smaller and more uniform microcarriers may be favorable for MSC growth within bioreactors and have greater potential to serve as a minimally invasive injectable cell delivery platform. To address these limitations, the current project focused on the development of a new microfluidic-based approach enabling both uniform and small microcarrier production. Using a novel, modified 3D T-junction design, we successfully generated microcarriers using human decellularized adipose tissue (DAT) as the ECM source. Our new cost-effective device produced microbeads that were small and monodisperse, at a range of flow rate combinations and with high production rates. Photo-crosslinking using rose bengal allowed for the generation of microcarriers that retained their shape and could withstand rehydration, with a mean diameter of 196 ± 47 μm. Following methods optimization and microcarrier characterization, in vitro studies confirmed that the new microcarriers supported human adipose-derived stromal cell (hASC) attachment and growth, as well as ECM production, across 14 days within spinner flask bioreactors. Overall, this study demonstrates the feasibility of using our novel, cost-effective, and reusable microfluidics device to generate cell-supportive microcarriers comprised exclusively of ECM that show promise as an MSC expansion platform.

Abstract Image

一个简单的,具有成本效益的微流体装置,使用3D交叉流t结生产脱细胞细胞外基质衍生的微载体
利用人间充质间质细胞(MSCs)进行细胞治疗具有广泛的临床应用前景。然而,在二维组织培养瓶中进行MSC扩增的传统培养方法限制了大规模的临床翻译。在搅拌生物反应器系统中,在ecm衍生的微载体上扩展MSC提供了一种支持MSC生长的有前途的方法。在此之前,我们的团队建立了使用电喷涂技术从各种脱细胞组织来源制造ecm衍生微载体的方法。然而,这些微载体相对较大,尺寸分布较广,这可能限制了它们的使用。更小、更均匀的微载体可能有利于MSC在生物反应器内的生长,并且有更大的潜力作为微创注射细胞递送平台。为了解决这些限制,目前的项目重点是开发一种新的基于微流体的方法,使微载体的生产既均匀又小。使用一种新颖的、改进的3D t结设计,我们成功地生成了以人类脱细胞脂肪组织(DAT)为ECM源的微载体。我们的新型低成本设备生产的微珠体积小,单分散,具有一定的流量组合和高产量。使用玫瑰红进行光交联可以生成微载体,微载体的平均直径为196±47 μm,可以保持其形状并承受再水化。经过方法优化和微载体表征,体外研究证实,新的微载体支持人脂肪源性基质细胞(hASC)在旋转烧瓶生物反应器中的附着和生长,以及ECM的产生,持续14天。总的来说,这项研究证明了使用我们新颖的、具有成本效益的、可重复使用的微流体设备产生细胞支持微载体的可行性,这些微载体完全由ECM组成,有望成为MSC扩展平台。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of biomedical materials research. Part A
Journal of biomedical materials research. Part A 工程技术-材料科学:生物材料
CiteScore
10.40
自引率
2.00%
发文量
135
审稿时长
3.6 months
期刊介绍: The Journal of Biomedical Materials Research Part A is an international, interdisciplinary, English-language publication of original contributions concerning studies of the preparation, performance, and evaluation of biomaterials; the chemical, physical, toxicological, and mechanical behavior of materials in physiological environments; and the response of blood and tissues to biomaterials. The Journal publishes peer-reviewed articles on all relevant biomaterial topics including the science and technology of alloys,polymers, ceramics, and reprocessed animal and human tissues in surgery,dentistry, artificial organs, and other medical devices. The Journal also publishes articles in interdisciplinary areas such as tissue engineering and controlled release technology where biomaterials play a significant role in the performance of the medical device. The Journal of Biomedical Materials Research is the official journal of the Society for Biomaterials (USA), the Japanese Society for Biomaterials, the Australasian Society for Biomaterials, and the Korean Society for Biomaterials. Articles are welcomed from all scientists. Membership in the Society for Biomaterials is not a prerequisite for submission.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信